- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00319267
Bosentan in Children With Pulmonary Arterial Hypertension (FUTURE-1)
May 23, 2016 updated by: Actelion
An Open Label, Multicenter Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Pediatric Formulation of Bosentan in Children With Idiopathic or Familial Pulmonary Arterial Hypertension
The aim of the study is to demonstrate that the exposure to bosentan in children with idiopathic pulmonary arterial hypertension (PAH) or familial pulmonary arterial hypertension, using a pediatric formulation, is similar to that in adults with PAH and to evaluate the tolerability and safety of a pediatric formulation of bosentan in this patient population.
Study Overview
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Clamart, France, 92140
- Hopital Antoine Beclere
-
Paris, France, 75743
- Hopital Necker
-
Toulouse, France
- CHE de Toulouse Hopital d'Enfants
-
-
-
-
-
Augustenburger, Germany
- Deutsches Herzzentrum
-
Giessen, Germany
- Universitats Kinderklinik
-
-
-
-
-
Bologna, Italy, 40138
- Policlinico S. Orsola-Malpighi
-
-
-
-
-
Groningen, Netherlands
- Beatrix Children's Hospital
-
-
-
-
-
Geneva, Switzerland
- Hopital des Enfants
-
-
-
-
-
London, United Kingdom
- The Institute of Child Health
-
-
-
-
Colorado
-
Denver, Colorado, United States, 80218
- The Children's Hospital Cardiac Care Center
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 12 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent by the parents or the legal representatives.
- Males or females >= 2 and < 12 years of age.
- Idiopathic PAH or familial PAH diagnosed by right heart catheterization (Clinical classification of pulmonary hypertension, Venice 2003).
- World Health Organization (WHO) functional class II or III.
- Oxygen saturation (SpO2) >= 88% (at rest, on room air).
PAH treatment-naïve patients or patients already treated with either:
- Bosentan monotherapy
- Intravenous epoprostenol monotherapy
- Intravenous or inhaled iloprost monotherapy
- Combination of bosentan and intravenous epoprostenol
- Combination of bosentan and intravenous or inhaled iloprost.
- All patients should start the study drug (bosentan pediatric formulation) at 2 mg/kg twice daily (b.i.d.), whether or not they were previously treated with bosentan.
- PAH therapy stable for at least 3 months prior to Screening.
- Stable treatment with calcium channel blockers, if any, for at least 3 months prior to Screening.
- Patient's PAH condition stable for at least 3 months prior to Screening.
Exclusion Criteria:
- PAH associated with conditions other than idiopathic or familial PAH.
- Non-stable patients, e.g., history (in the last 3 months prior to Screening) of recurrent syncope, or signs and symptoms of non-compensated right heart failure.
- Need or plan to wean patients from intravenous epoprostenol, or intravenous, or inhaled iloprost.
- Body weight < 4 kg.
- Systolic blood pressure < 80%, the lower limit of normal range, according to age and gender.
- AST and/or ALT values > 3 times the upper limit of normal ranges.
- Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
- Hemoglobin and/or hematocrit levels < 75% of the lower limit of normal ranges.
- Pregnancy.
- Known intolerance or hypersensitivity to bosentan or any of the excipients.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bosentan
The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks.
After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12.
If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
|
Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration-time curve during a dose interval (AUCt) for bosentan
Time Frame: At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose
|
AUCt was assessed at steady state (i.e., after at least 2 weeks of treatment with a same dose of the study drug) over 12 hours .
|
At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax) of bosentan and its metabolites
Time Frame: At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose
|
Maximum observed plasma concentration for bosentan and its metabolites was directly derived from their respective plasma concentration-time curves.
|
At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose
|
Time to reach the maximum plasma concentration (tmax) of bosentan and its metabolites
Time Frame: At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose
|
At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose
|
|
Area under the plasma concentration-time curve during a dose interval (AUCt) for the metabolites of bosentan
Time Frame: At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose
|
AUCt was assessed at steady state (i.e., after at least 2 weeks of treatment with a same dose of the study drug) over 12 hours.
|
At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
December 1, 2006
Study Completion (Actual)
February 1, 2007
Study Registration Dates
First Submitted
April 26, 2006
First Submitted That Met QC Criteria
April 26, 2006
First Posted (Estimate)
April 27, 2006
Study Record Updates
Last Update Posted (Estimate)
May 24, 2016
Last Update Submitted That Met QC Criteria
May 23, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension, Pulmonary
- Hypertension
- Pulmonary Arterial Hypertension
- Familial Primary Pulmonary Hypertension
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Endothelin Receptor Antagonists
- Bosentan
Other Study ID Numbers
- AC-052-365
- 2004-005157-63 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Bosentan
-
ActelionCompletedDigital UlcersFrance, United Kingdom, United States, Austria, Canada, Germany, Italy, Switzerland
-
GeropharmCompletedBioequivalenceRussian Federation
-
ActelionCompletedSystemic Sclerosis | Digital UlcersUnited States, Canada
-
ActelionCompletedPulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCanada, United Kingdom, Italy, United States, Netherlands, Australia, Austria, Belgium, France, Germany, Spain
-
ActelionCompletedPulmonary HypertensionUnited States, Canada, Australia, Germany, Italy, United Kingdom, France, Austria, Belgium, Czech Republic, Netherlands, Poland, Spain
-
Medical University of ViennaCompletedGlaucoma | Blood Flow VelocityAustria
-
ActelionCompletedInterstitial Lung Disease | SclerodermaUnited States, Korea, Republic of, Israel, France, United Kingdom, Netherlands, Switzerland, Germany, Canada, Italy, Sweden
-
General Hospital of ChalkidaUnknownSECONDARY PULMONARY HYPERTENSION | MITRAL STENOSIS | CHILDHOOD RHEUMATOID FEVER | CONGESTIVE HEART FAILUREGreece
-
Rikshospitalet University HospitalTerminated
-
Rajan SaggarActelionWithdrawnIdiopathic Pulmonary Fibrosis | Pulmonary Arterial HypertensionUnited States